Vilanterol is a long-acting beta2-adrenergic agonist used in combination with other bronchodilators for the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma.
- Mechanism
- Curator reviewed
Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs.
- Primary indication
- Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta, in combination with umeclidinium bromide as Anoro Ellipta, and in combination with both fluticasone furoate and...Curator reviewed · 5 structured indications
- Formula / weight
- C24H33Cl2NO5 · 486.43 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2013 · European Union, 2016
- Code names
- GW-642444 · GW-642444M · GW-642444X
- Brand names
Resolves to
DAFYYTQWSAWIGS-DEOSSOPVSA-NSMILESOCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1ClWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Vilanterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account